Company Profile
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows:
- dialysis treatment (46.8%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.;
- hospital administration and engineering (34.2%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.;
- perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc.
Net sales are distributed geographically as follows: Europe (45%), North America (38.3%), Asia/Pacific (10.5%), Latin America (4.9%) and Africa (1.3%).
- dialysis treatment (46.8%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.;
- hospital administration and engineering (34.2%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.;
- perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc.
Net sales are distributed geographically as follows: Europe (45%), North America (38.3%), Asia/Pacific (10.5%), Latin America (4.9%) and Africa (1.3%).
Source: Cofisem - Last Update: 2023-05-18
Key Executives
| Chairman of the Management Board | |
| Member of the Management Board | |
| Member of the Management Board | |
| Member of the Management Board | |
| Chief Financial Officer | |
| Human Resources Director | |
| General Counsel | |
| Investor Relations Director | |
| VP, Communication |
Source: Cofisem - Last Update: 2023-05-02
Key Figures
| Millenium | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Net sales | 40,840,000 | 37,520,000 | 36,277,000 | 35,409,000 | 33,530,000 |
| Income from ordinary activities | 40,840,000 | 37,520,000 | 36,277,000 | 35,409,000 | 33,530,000 |
| Operating income | 3,321,000 | 4,158,000 | 4,385,000 | 4,631,000 | 5,251,000 |
| Cost of financial indebtedness net | 507,000 | 506,000 | 659,000 | 719,000 | 587,000 |
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | |||||
| Net income | 2,117,000 | 2,819,000 | 2,823,000 | 3,029,000 | 3,714,000 |
| Net income (Group share) | 1,372,000 | 1,818,000 | 1,707,000 | 1,883,000 | 2,027,000 |
| Fiscal year end | 12.22 | 12.21 | 12.2 | 12.19 | 12.18 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards |
Source: Cofisem - Last Update: 2023-05-18
Shareholder information
| Institutional shareholders | |
| Else Kröner-Fresenius Foundation | |
| Other shareholders |
Source: Cofisem - Last Update: 2023-05-18
Address
Fresenius SE & Co. KGaA
Else-Kröner-Strasse 1
DE-61352 Bad Homburg vor der Höhe, Hessen
Germany
Phone number: +49 (0) 6172 608 0
https://www.fresenius.com
Source: Cofisem - Last Update: 2023-05-18
Please contact MyQuestion.Italy@euronext.com for Company Profile support.